A Modified Lateral Lumbar Interbody Fusion VS. Transforaminal Lumbar Interbody Fusion for Adult Degenerative Scoliosis

Sponsor
Second Affiliated Hospital, School of Medicine, Zhejiang University (Other)
Overall Status
Recruiting
CT.gov ID
NCT04071665
Collaborator
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School (Other), First Affiliated Hospital of Shantou University Medical College (Other), Shenzhen University (Other)
350
1
2
32
10.9

Study Details

Study Description

Brief Summary

A modified lateral lumbar interbody fusion VS. transforaminal lumbar interbody fusion for the treatment of adult degenerative scoliosis with 2 year follow-up with a multiple center, randomized case-control study

Condition or Disease Intervention/Treatment Phase
  • Procedure: Modified lateral lumbar interbody fusion
N/A

Detailed Description

Adult degenerative scoliosis (ADS) is the most common spinal deformity in the elderly, and the severe patients need surgical treatment. The elderly are often complicated with many medical diseases and the perioperative risk is high, so minimally invasive surgery is a new choice for spinal surgeons to treat ADS. Modified lateral lumbar interbody fusion (CLIF) is an new modified spinal minimally invasive interbody fusion technique in the investigator's department. The results of preliminary studies showed that it has the advantages of less trauma, short operation time and fewer complications, and the clinical and imaging outcome are remarkable. Therefore, the present study aims to establish a multicenter, large sample prospective randomized controlled study to explore the technical advantages and surgical indications of the new technique in the treatment of ADS by comparing with the traditional posterior spinal interbody fusion; (2) to compare the postoperative clinical and imaging results and analyze the surgical complications and preventive measures; (3) to establish a long-term follow-up to further quantify the clinical and imaging outcome of the new technique. Therefore, this study will further verify the safety and effectiveness of the CLIF in the treatment of ADS on the basis of previous studies, and provide a new clinical approach for minimally invasive treatment of ADS.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
350 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Participant)
Primary Purpose:
Treatment
Official Title:
A Modified Lateral Lumbar Interbody Fusion VS. Transforaminal Lumbar Interbody Fusion for Adult Degenerative Scoliosis
Anticipated Study Start Date :
May 1, 2020
Anticipated Primary Completion Date :
Jan 1, 2021
Anticipated Study Completion Date :
Dec 31, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: Modified lateral lumbar interbody fusion

Modified lateral lumbar interbody fusion for treatment of scoliosis

Procedure: Modified lateral lumbar interbody fusion
Modified lateral lumbar interbody fusion

Active Comparator: transforaminal lumbar interbody fusion

transforaminal lumbar interbody fusion

Procedure: Modified lateral lumbar interbody fusion
Modified lateral lumbar interbody fusion

Outcome Measures

Primary Outcome Measures

  1. ODI score [2 years]

    an index for assessing the lower back pain wiith multiple questionnare

Eligibility Criteria

Criteria

Ages Eligible for Study:
50 Years to 75 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • at least 50 years of age, diagnosed with adult thoracolumbar scoliosis including any number of intervertebral levels between T8 and S1, unresponsive to conservative treatment for at least 6 months, and had a preoperative coronal Cobb angle of at least 10° and preoperative ODI score of at least 30%.
Exclusion Criteria:
  • with prior lumbar fusion surgery or spondylolisthesis greater than Grade II

Contacts and Locations

Locations

Site City State Country Postal Code
1 Second Affiliated Hospital, School of Medicine, Zejiang University Hangzhou Zhejiang China 310000

Sponsors and Collaborators

  • Second Affiliated Hospital, School of Medicine, Zhejiang University
  • The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
  • First Affiliated Hospital of Shantou University Medical College
  • Shenzhen University

Investigators

  • Study Director: Qixin CHEN, Ph.D, Orthopedics Department, 2nd Hospital, School of Medicine, Zhejiang University

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Second Affiliated Hospital, School of Medicine, Zhejiang University
ClinicalTrials.gov Identifier:
NCT04071665
Other Study ID Numbers:
  • NSFC 81702220
First Posted:
Aug 28, 2019
Last Update Posted:
May 12, 2020
Last Verified:
Jun 1, 2019
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of May 12, 2020